Diagnostic and therapeutic challenges in implementing hypertension management after kidney transplantation

Ekamol Tantisattamo1,2,3,4, Antoney J Ferrey1, Uttam G Reddy1

  • 1American Heart Association Comprehensive Hypertension Center at the University of California Irvine Medical Center, Division of Nephrology, Hypertension and Kidney Transplantation, Department of Medicine, University of California Irvine School of Medicine, Orange, California.

Insights

Accurate blood pressure (BP) measurement and hypertension management are crucial for kidney transplant recipients (KTR). Guidelines should consider post-transplant factors, with 24-h ambulatory BP monitoring as the gold standard for diagnosis.

Area of Science:

  • Nephrology
  • Cardiology
  • Transplant Medicine

Background:

  • Hypertension is a common complication in kidney transplant recipients (KTR).
  • Standardized evidence for BP measurement and hypertension management in KTR is limited.
  • Post-transplant factors influence BP and require tailored management strategies.

Purpose of the Study:

  • To review current evidence and provide guidance on BP measurement and hypertension management in KTR.
  • To highlight the importance of accurate BP monitoring techniques.
  • To discuss BP targets and therapeutic options in the context of kidney transplantation.

Main Methods:

  • Review of current literature on BP measurement and hypertension in KTR.
  • Analysis of factors influencing BP post-transplantation.
  • Discussion of diagnostic gold standards and therapeutic approaches.

Main Results:

  • 24-h ambulatory BP monitoring is the gold standard for diagnosing hypertension in KTR.
  • BP targets may differ from non-transplant patients due to factors like vascular calcification and immunosuppression.
  • Specific BP targets are proposed for immediate, early, and late post-transplant periods.
  • Calcium channel blockers show favorable graft outcomes.
  • Novel treatments are limited by trial ineligibility.

Conclusions:

  • BP measurement and monitoring in KTR should adapt standard guidelines considering post-transplant factors and immunosuppression.
  • Further research is needed for novel treatment options in KTR hypertension.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
461
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
495
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
623